Reuters: US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's (NOVOb.CO), controlling shareholder would acquire contract drug manufacturer Catalent (CTLT.N), saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.

Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost supply of Wegovy, Novo's blockbuster GLP-1 weight loss drug.

Warren urged the U.S. Federal Trade Commission to sue to block the deal, opens new tab if the regulator finds it illegal – which could delay the deal's expected closing later this year.

…

Read the full story here.

• Print
• Email
• Tweet